Glycyrrhizic acid Attenuates Neuroinflammation and Oxidative Stress in Rotenone Model of Parkinson’s Disease

Neurotoxicity Research

Volumn 29, Issue 2, 2016, Pages 275-287

  Ojha, Shreesh ^a   Javed, Hayate ^a   Azimullah, Sheikh ^a   Abul Khair, Salema B ^a   Haque, M Emdadul ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Glycyrrhizic acid; Inflammation; Neurodegeneration; Oxidative stress; Parkinson s disease; Rotenone

Indexed keywords

CATALASE; CYCLOOXYGENASE 2; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; GLYCYRRHIZIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; MALONALDEHYDE; MEMBRANE PROTEIN; ROTENONE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; AUTACOID; CALCIUM BINDING PROTEIN; NOS2 PROTEIN, RAT; PTGS2 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN LEVEL; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED; CORPUS STRIATUM; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; PARKINSONIAN DISORDERS; WISTAR RAT;

ANIMALS; CALCIUM-BINDING PROTEINS; CATALASE; CORPUS STRIATUM; CYCLOOXYGENASE 2; CYTOKINES; DOPAMINERGIC NEURONS; ENCEPHALITIS; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; GLYCYRRHIZIC ACID; INFLAMMATION MEDIATORS; LIPID PEROXIDATION; MALE; MICROFILAMENT PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; ROTENONE; SUPEROXIDE DISMUTASE;

EID: 84954360343     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-015-9579-z     Document Type: Article

References (37)

1. Al Dakheel A, Kalia LV, Lang AE (2014) Pathogenesis-targeted disease-modifying therapies in Parkinson disease. Neurotherapeutics 11:6–23
2. Albarracin SL, Stab B, Casas Z, Sutachan JJ, Samudio I, Gonzalez J, Gonzalo L, Capani F, Morales L, Barreto GE (2012) Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 15:1–9
3. Anderson G, Maes M (2014) Neurodegeneration in Parkinson’s disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins. Mol Neurobiol 49:771–783
4. Asl MN, Hosseinzadeh H (2008) Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 22:709–724
5. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306
6. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT (2009) A highly reproducible Rotenone model of Parkinson’s disease. Neurobiol Dis 34:279–290
7. Celardo I, Martins LM, Gandhi S (2014) Unravelling mitochondrial pathways to Parkinson's disease. Br J Pharmacol 171(8):1943–1957
8. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6
9. Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132–144
10. Fu SP, Wang JF, Xue WJ, Liu HM, Liu BR, Zeng YL, Li SN, Huang BX, Lv QK, Wang W, Liu JX (2015) Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation 12:9
11. Fujikawa T, Kanada N, Shimada A, Ogata M, Suzuki I, Hayashi I, Nakashima K (2005) Effect of sesamin in Acanthopanax senticosus HARMS on behavioral dysfunction in rotenone-induced parkinsonian rats. Biol Pharm Bull 28:169–172
12. Gong G, Xiang L, Yuan L, Hu L, Wu W, Cai L, Yin L, Dong H (2014) Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats. PLoS ONE 9:e89450
13. Hartlage-Rübsamen M, Lemke R, Schliebs R (1999) Interleukin-1β, inducible nitric oxide synthase, and nuclear factor-κB are induced in morphologically distinct microglia after rat hippocampal lipopolysaccharide/interferon-γ injection. J Neurosci Res 57:388–398
14. Johnson ME, Bobrovskaya L (2014) An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 46C:101–116
15. Kawakami Z, Ikarashi Y, Kase Y (2010) Glycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol 626:154–158
16. Koppula S, Kumar H, More SV, Lim HW, Hong SM, Choi DK (2012) Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson’s disease. Molecules 17:11391–11420
17. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7:1291–1297
18. Litteljohn D, Mangano E, Clarke M, Bobyn J, Moloney K, Hayley S (2011) Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson’s disease. Parkinson’s Dis 2010:713517
19. Luo L, Jin Y, Kim ID, Lee JK (2013) Glycyrrhizin attenuates kainic Acid-induced neuronal cell death in the mouse hippocampus. Exp Neurobiol 22:107–115
20. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson’s disease. Exp Neurol 235:528–538
21. Mazzio E, Deiab S, Park K, Soliman KF (2013) High throughput screening to identify natural human monoamine oxidase B inhibitors. Phytother Res 27:818–828
22. Niranjan R (2014) The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol Neurobiol 49:28–38
23. Ojha S, Golechha M, Kumari S, Bhatia J, Arya DS (2013) Glycyrrhiza glabra protects from myocardial ischemia-reperfusion injury by improving hemodynamic, biochemical, histopathological and ventricular function. Exp Toxicol Pathol 65:219–227
24. Pigeolet E, Corbisier P, Houbion A, Lambert D, Michiels C, Raes M, Zachary MD, Remacle J (1990) Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev 51:283–297
25. Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet 384:545–555
26. Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341:87–90
27. Shishkina GT, Dygalo NN, Yudina AM, Kalinina TS, Tolstikova TG, Sorokina IV, Kovalenko IL, Anikina LV (2006) The effects of fluoxetine and its complexes with glycyrrhizic acid on behavior in rats and brain monoamine levels. Neurosci Behav Physiol 36:329–333
28. Song JX, Sze SC, Ng TB, Lee CK, Leung GP, Shaw PC, Tong Y, Zhang YB (2012) Anti-Parkinsonian drug discovery from herbal medicines: what have we got from neurotoxic models? J Ethnopharmacol 139:698–711
29. Song JH, Lee JW, Shim B, Lee CY, Choi S, Kang C, Sohn NW, Shin JW (2013) Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. Molecules 18:15788–15803
30. Takeda A, Nyssen OP, Syed A, Jansen E, Bueno-de-Mesquita B, Gallo V (2014) Vitamin A and carotenoids and the risk of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology 42:25–38
31. Taylor JM, Main BS, Crack PJ (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson’s disease. Neurochem Int 62:803–819
32. Teng L, Kou C, Lu C, Xu J, Xie J, Lu J, Liu Y, Wang Z, Wang D (2014) Involvement of the ERK pathway in the protective effects of glycyrrhizic acid against the MPP + -induced apoptosis of dopaminergic neuronal cells. Int J Mol Med 34:742–748
33. Verma R, Nehru B (2009) Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem Int 55:369–375
34. Wang D, Guo TQ, Wang ZY, Lu JH, Liu DP, Meng QF, Xie J, Zhang XL, Liu Y, Teng LS (2014) ERKs and mitochondria-related pathways are essential for glycyrrhizic acid-mediated neuroprotection against glutamate-induced toxicity in differentiated PC12 cells. Braz J Med Biol Res 47:773–779
35. Xiong N, Huang J, Chen C, Zhao Y, Zhang Z, Jia M, Zhang Z, Hou L, Yang H, Cao X, Liang Z, Zhang Y, Sun S, Lin Z, Wang T (2012) Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson’s disease. Neurobiol Aging 33:1777–1791
36. Yoke Yin C, So Ha T, Abdul Kadir K (2010) Effects of glycyrrhizic acid on peroxisome proliferator-activated receptor gamma (PPAR-gamma), lipoprotein lipase (LPL), serum lipid and HOMA-IR in rats. PPAR Res 2010:530265
37. Zhu X, Chen C, Ye D, Guan D, Ye L, Jin J, Zhao H, Chen Y, Wang Z, Wang X, Xu Y (2012) Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicity. PLoS ONE 7:e35823